Thomas Dayspring, MD, FACP, FNLA
MD; clinical lipidologist; Fellow of the American College of Physicians and the National Lipid Association
One of the most prominent clinical-lipidology educators, known for detailed teaching on apoB, lipoprotein particle number, and lipid metabolism to both clinicians and the public. He served as chief academic advisor to two major cardiovascular laboratories until mid-2019. Within this debate he is a strong mainstream voice: he regards apoB-containing lipoproteins as the central causal driver of atherosclerosis and favours measuring and aggressively lowering apoB.
Position (a lossy summary - the nuance is below)
LDL: benign to causal
+0.90 (strongly toward "LDL causal")
Dayspring is one of the most emphatic mainstream voices that apoB-containing lipoproteins (LDL chief among them) are the primary causal driver of atherosclerosis, citing epidemiologic, genetic, and trial evidence together. He sits near the causal pole; he is not at the absolute extreme only because, like Attia, he stresses that apoB rather than LDL-C is the right way to quantify the exposure.
Statins: anti to pro
+0.90 (strongly toward "Pro-statin")
Strongly pro lipid-lowering therapy. He argues a physiologic apoB is well below typical population levels and supports lifestyle plus pharmacologic apoB-lowering therapy to reach low targets, especially in higher-risk patients. His position is treat-to-low-apoB rather than treat-by-LDL-C-threshold.
The strongest specialist counterweight on the mainstream side: a career lipidologist who holds that apoB lipoproteins cause atherosclerosis and that the practical task is to measure apoB and lower it, early and substantially, in people at risk. To a metabolically healthy person with a high LDL he would still want the apoB measured and, if high, treated.
Key arguments
- apoB (particle number) is the superior risk marker and the better treatment target than LDL-C.
- apoB-containing lipoproteins are a causal driver of atherosclerosis, supported by epidemiology, genetics, and trials together.
- When apoB and LDL-C are discordant, risk tracks apoB.
- A physiologic apoB is well below typical population levels; aggressive lowering is warranted in higher-risk patients.
Positions on specific claims
- Does LDL cholesterol actually cause heart disease?
Strongly agrees that apoB-bearing lipoproteins, including LDL, causally drive atherosclerosis; frames LDL-C as a sometimes-misleading proxy for the apoB particle burden that actually matters.
- Is ApoB a better measure of risk than standard LDL cholesterol?
Strongly endorses apoB as a superior test to LDL-C, emphasising apoB/LDL-C discordance and apoB targets for low- and high-risk patients.
Conflicts of interest
Professional identity and prominence are tied to advanced lipid testing and apoB education: he served as chief academic advisor to two major cardiovascular laboratories until mid-2019 (per the cited interview). This aligns his incentives with wider apoB testing and lipid-lowering treatment - disclosed here on the same footing as the book/supplement incomes recorded for skeptics. Any current industry or speaking relationships were not verified this session and are not asserted here.
Fair criticisms
- Skeptics argue his low apoB targets and enthusiasm for treating lower-risk people extrapolate beyond direct outcome-trial evidence in those groups.
- His close identification with the advanced-lipid-testing industry is a potential source of bias toward more testing and treatment.